A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-PositiveRecurrent or Metastatic Breast Cancer
Interventions: DRUG: SHR-A1811 Injection|DRUG: SHR-A1811 Injection ； Pertuzumab Injection|DRUG: Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
Sponsor: Jiangsu HengRui Medicine Co., Ltd.